QQQ   281.64 (-0.01%)
AAPL   141.94 (-0.68%)
MSFT   245.68 (+0.23%)
META   114.60 (+0.42%)
GOOGL   95.94 (-1.07%)
AMZN   89.02 (+0.87%)
TSLA   174.62 (-2.89%)
NVDA   160.45 (+0.36%)
NIO   12.38 (-6.50%)
BABA   88.20 (-3.55%)
AMD   70.62 (+0.50%)
T   19.41 (+1.25%)
MU   53.85 (+0.32%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.44 (+0.16%)
AMC   6.72 (-0.44%)
PYPL   72.45 (+0.30%)
PFE   50.55 (+1.69%)
NFLX   306.86 (+0.43%)
QQQ   281.64 (-0.01%)
AAPL   141.94 (-0.68%)
MSFT   245.68 (+0.23%)
META   114.60 (+0.42%)
GOOGL   95.94 (-1.07%)
AMZN   89.02 (+0.87%)
TSLA   174.62 (-2.89%)
NVDA   160.45 (+0.36%)
NIO   12.38 (-6.50%)
BABA   88.20 (-3.55%)
AMD   70.62 (+0.50%)
T   19.41 (+1.25%)
MU   53.85 (+0.32%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.44 (+0.16%)
AMC   6.72 (-0.44%)
PYPL   72.45 (+0.30%)
PFE   50.55 (+1.69%)
NFLX   306.86 (+0.43%)
QQQ   281.64 (-0.01%)
AAPL   141.94 (-0.68%)
MSFT   245.68 (+0.23%)
META   114.60 (+0.42%)
GOOGL   95.94 (-1.07%)
AMZN   89.02 (+0.87%)
TSLA   174.62 (-2.89%)
NVDA   160.45 (+0.36%)
NIO   12.38 (-6.50%)
BABA   88.20 (-3.55%)
AMD   70.62 (+0.50%)
T   19.41 (+1.25%)
MU   53.85 (+0.32%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.44 (+0.16%)
AMC   6.72 (-0.44%)
PYPL   72.45 (+0.30%)
PFE   50.55 (+1.69%)
NFLX   306.86 (+0.43%)
QQQ   281.64 (-0.01%)
AAPL   141.94 (-0.68%)
MSFT   245.68 (+0.23%)
META   114.60 (+0.42%)
GOOGL   95.94 (-1.07%)
AMZN   89.02 (+0.87%)
TSLA   174.62 (-2.89%)
NVDA   160.45 (+0.36%)
NIO   12.38 (-6.50%)
BABA   88.20 (-3.55%)
AMD   70.62 (+0.50%)
T   19.41 (+1.25%)
MU   53.85 (+0.32%)
CGC   3.43 (-4.99%)
F   13.36 (+0.60%)
GE   86.03 (+0.88%)
DIS   92.44 (+0.16%)
AMC   6.72 (-0.44%)
PYPL   72.45 (+0.30%)
PFE   50.55 (+1.69%)
NFLX   306.86 (+0.43%)
OTCMKTS:BMXMF

bioMérieux - BMXMF Stock Forecast, Price & News

$98.10
-4.25 (-4.15%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$98.10
▼
$98.10
50-Day Range
$78.36
▼
$104.00
52-Week Range
$78.06
▼
$143.65
Volume
200 shs
Average Volume
33 shs
Market Capitalization
$11.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$99.35

bioMérieux MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.3% Upside
$99.35 Price Target
Short Interest
Bearish
0.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.69 out of 5 stars

See Top Rated MarketRank™ Stocks Here
BMXMF stock logo

About bioMérieux (OTCMKTS:BMXMF) Stock

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

BMXMF Stock News Headlines

October 26, 2022 | msn.com
bioMerieux : les résultats 2022 devraient se situer dans la borne haute des intervalles publiés en août
April 13, 2022 | msn.com
bioMerieux : du mieux
April 12, 2022 | msn.com
bioMerieux recule après les annonces
March 3, 2022 | seekingalpha.com
bioMérieux S.A. GAAP EPS of €5.06, revenue of €3.37M
January 7, 2022 | finance.yahoo.com
French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
October 21, 2021 | finance.yahoo.com
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
October 5, 2021 | finance.yahoo.com
bioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021
March 23, 2021 | finanznachrichten.de
bioMérieux - 2020 Financial Results
September 29, 2020 | finanznachrichten.de
bioMérieux - First-Half 2020 Results
September 27, 2020 | finance.yahoo.com
French labs show how global supply bottlenecks thwart effort to ramp up testing
September 10, 2020 | finance.yahoo.com
What Makes BIOMERIEUX (BMXMF) a New Buy Stock
September 5, 2020 | marketwatch.com
COVID-19 Diagnostics Market Clinical Reviews by Expert and Healthcare Analysis 2020
September 3, 2020 | seekingalpha.com
bioMérieux SA (BMXMF) CEO Alexandre Mérieux on Q2 2020 Results - Earnings Call Transcript
September 2, 2020 | seekingalpha.com
bioMérieux S.A. 2020 Q2 - Results - Earnings Call Presentation
July 27, 2020 | finance.yahoo.com
What Makes BIOMERIEUX (BMXMF) a New Strong Buy Stock
July 15, 2020 | finance.yahoo.com
BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
June 30, 2020 | finance.yahoo.com
bioMérieux: Description of the New Share Buyback Program Pursuant to Article 241-1 to Article 241-6 of the AMF General Regulations
June 29, 2020 | finance.yahoo.com
bioMérieux Issues a €200 Million Euro PP Bond
May 30, 2020 | finance.yahoo.com
Drugs standards group nixes plan to kick pharma's crab blood habit
May 27, 2020 | finance.yahoo.com
All You Need to Know About BIOMERIEUX (BMXMF) Rating Upgrade to Buy
May 23, 2020 | finance.yahoo.com
bioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
May 21, 2020 | finance.yahoo.com
CE Marking of bioMérieux Serology Tests for SARS-CoV-2 on VIDAS®
May 19, 2020 | finance.yahoo.com
Information Concerning 2019 Dividend and the bioMérieux General Shareholders’ Meeting
May 6, 2020 | finance.yahoo.com
bioMérieux Serology Tests for SARS-CoV-2 on VIDAS® Undergo Validation Preceding Imminent Launch
May 4, 2020 | finance.yahoo.com
bioMérieux S.A. (EPA:BIM) Earns A Nice Return On Capital Employed
See More Headlines
Receive BMXMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioMérieux and its competitors with MarketBeat's FREE daily newsletter.

BMXMF Company Calendar

Today
12/07/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BMXMF
CUSIP
N/A
CIK
N/A
Web
www.biomerieux.com
Phone
33-04-78-87-20-00
Fax
33-04-78-87-20-90
Employees
13,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$99.35
High Stock Price Forecast
$109.00
Low Stock Price Forecast
$89.70
Forecasted Upside/Downside
+1.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
2.02
Quick Ratio
1.33

Sales & Book Value

Annual Sales
$3.99 billion
Price / Sales
2.91
Cash Flow
$7.97 per share
Price / Cash Flow
12.31
Book Value
$31.73 per share
Price / Book
3.09

Miscellaneous

Outstanding Shares
118,360,000
Free Float
N/A
Market Cap
$11.61 billion
Optionable
Not Optionable
Beta
1.00

Key Executives

  • Mr. Alexandre Merieux (Age 48)
    Chairman & CEO
    Comp: $1.57M
  • Mr. Pierre Boulud (Age 51)
    Chief Operating Officer of Clinical Operations
    Comp: $1.18M
  • Mr. Frederic Beseme (Age 66)
    Head of CSR
    Comp: $35.86k
  • Mr. Guillaume Bouhours (Age 46)
    Exec. VP of Purchasing and Information Systems & CFO
  • Sylvain Morgeau
    Investor Relations
  • Ms. Valerie Leylde
    Exec. VP of HR, Communications & CSR
  • Mr. François Lacoste
    Exec. VP of R&D
  • Mr. Mark Miller
    Exec. VP of Medical Affairs
  • Mr. Pierre Charbonnier
    Exec. VP of Quality, Manufacturing & Supply Chain
  • Mr. Yasha Mitrotti
    Exec. VP of Industrial Microbiology

Key Competitors

View All Competitors













BMXMF Stock - Frequently Asked Questions

Should I buy or sell bioMérieux stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMXMF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View BMXMF analyst ratings or view top-rated stocks.

What is bioMérieux's stock price forecast for 2023?

4 brokers have issued 1 year price objectives for bioMérieux's shares. Their BMXMF share price forecasts range from $89.70 to $109.00. On average, they expect the company's stock price to reach $99.35 in the next year. This suggests a possible upside of 1.3% from the stock's current price.
View analysts price targets for BMXMF or view top-rated stocks among Wall Street analysts.

How have BMXMF shares performed in 2022?

bioMérieux's stock was trading at $140.00 on January 1st, 2022. Since then, BMXMF stock has decreased by 29.9% and is now trading at $98.10.
View the best growth stocks for 2022 here.

Are investors shorting bioMérieux?

bioMérieux saw a increase in short interest in October. As of October 31st, there was short interest totaling 223,800 shares, an increase of 31.1% from the October 15th total of 170,700 shares. Based on an average trading volume of 300 shares, the days-to-cover ratio is presently 746.0 days.
View bioMérieux's Short Interest.

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $98.10.

How much money does bioMérieux make?

bioMérieux (OTCMKTS:BMXMF) has a market capitalization of $11.61 billion and generates $3.99 billion in revenue each year.

How many employees does bioMérieux have?

The company employs 13,000 workers across the globe.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The official website for the company is www.biomerieux.com. The company can be reached via phone at 33-04-78-87-20-00, via email at investor.relations@biomerieux.com, or via fax at 33-04-78-87-20-90.

This page (OTCMKTS:BMXMF) was last updated on 12/7/2022 by MarketBeat.com Staff